Phase ii trial of pharmacogenetic guided beta-blocker therapy with bucindolol vs. metoprolol for the prevention of atrial fibrillation/flutter in heart failure: GENETIC-AF
27 May 2018 (09:00 - 09:10)
Organised by:
Slides
About the speaker
The Ohio State University, Columbus (United States of America)
11 More presentations in this session
Professor D. Kotecha (Birmingham, GB)
Access the full session
The Event
Heart Failure 2018
27 May 2018
09:00 CET
You may be interested in
Congress Session
Congress Presentation
